Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Sarcoidosis | Research

Immunoreactivity to metal and silica associates with sarcoidosis in Dutch patients

Authors: E. Beijer, B. Meek, X. Bossuyt, S. Peters, R. C. H. Vermeulen, H. Kromhout, M. Veltkamp

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

Involvement of metals or silica in the pathogenesis of sarcoidosis has been suggested by several case reports and specific epidemiological studies. However, the combination of occupational exposure and an immunological reaction has not been studied before in a group of sarcoidosis patients and non-sarcoidosis controls.

Methods

In 256 sarcoidosis patients and 73 control patients with obstructive sleep apnea, exposure to metal and silica was assessed using a questionnaire consisting of a complete occupational history subsequently linked to job-exposure matrices. Next, immunoreactivity to aluminium, beryllium, zirconium and silica was determined in 33 sarcoidosis and 19 control patients using a lymphocyte proliferation test.

Results

In sarcoidosis, 83 out 256 patients (32.4%) had occupational exposure to metals or silica, compared to 24.7% in the control group (p = 0.21). A significantly higher percentage of the sarcoidosis patients tested showed immunoreactivity to metals or silica compared to the control group (21.2 and 0% respectively, p = 0.039).

Conclusions

Immunoreactivity to silica and metals was only found in sarcoidosis patients, supporting the hypothesis that these antigens may be involved in the pathogenesis of a distinct subgroup of sarcoidosis patients. This indicates that when searching for causative agents in sarcoidosis patients, besides beryllium, also zirconium, aluminium and silica deserve clinical investigation.
Appendix
Available only for authorised users
Literature
1.
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–9.CrossRef
2.
Mayer AS, Hamzeh N, Maier LA. Sarcoidosis and chronic beryllium disease: similarities and differences. Semin Respir Crit Care Med. 2014;35(3):316–29.CrossRef
3.
Werfel U, Schneider J, Rodelsperger K, Kotter J, Popp W, Woitowitz HJ, et al. Sarcoid granulomatosis after zirconium exposure with multiple organ involvement. Eur Respir J. 1998;12(3):750.CrossRef
4.
Rafnsson V, Ingimarsson O, Hjalmarsson I, Gunnarsdottir H. Association between exposure to crystalline silica and risk of sarcoidosis. Occup Environ Med. 1998;55(10):657–60.CrossRef
5.
Tomioka H, Kaneda T, Katsuyama E, Kitaichi M, Moriyama H, Suzuki E. Elemental analysis of occupational granulomatous lung disease by electron probe microanalyzer with wavelength dispersive spectrometer: two case reports. Respir Med case reports. 2016;18:66–72.
6.
Drent M, Bomans PH, Van Suylen RJ, Lamers RJ, Bast A, Wouters EF. Association of man-made mineral fibre exposure and sarcoidlike granulomas. Respir Med. 2000;94(8):815–20.CrossRef
7.
Cao M, Cai HR, Meng FQ, Wei JY. Pulmonary sarcoidlike granulomatosis induced by aluminum dust: a case report and literature review. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31(6):406–9.PubMed
8.
Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest. 2004;126(6):2000–7.CrossRef
9.
Sprince NL, Kanarek DJ, Weber AL, Chamberlin RI, Kazemi H. Reversible respiratory disease in beryllium workers. Am Rev Respir Dis. 1978;117(6):1011–7.PubMed
10.
Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735–7.CrossRef
11.
Maspero C, Giannini L, Galbiati G, Rosso G, Farronato G. Obstructive sleep apnea syndrome: a literature review. Minerva Stomatol. 64(2):97–109.
12.
International Labour Office; Geneva. International Standard Classification of Occupations. Revised edition 1968. International Labor Office, Washington Branch, 917 15th Street, N.W, Washington, D.C. 20005 ($5.00); 1969. 362.
13.
Peters S, Vermeulen R, Cassidy A, Mannetje A, van Tongeren M, Boffetta P, et al. Comparison of exposure assessment methods for occupational carcinogens in a multi-Centre lung cancer case-control study. Occup Environ Med. 2011;68(2):148–53.CrossRef
14.
SUNYER J, KOGEVINAS M, KROMHOUT H, ANTÓ JM, ROCA J, TOBIAS A, et al. Pulmonary Ventilatory defects and occupational exposures in a population-based study in Spain. Am J Respir Crit Care Med. 1998;157(2):512–7.CrossRef
15.
International Labour Office. International standard classification of occupations: ISCO-88. Geneva: International Labour Organization; 1990.
16.
Stejskal VD, Cederbrant K, Lindvall A, Forsbeck M. MELISA-an in vitro tool for the study of metal allergy. Toxicol in Vitro. 1994;8(5):991–1000.CrossRef
17.
Valentine-Thon E, Schiwara H-W. Validity of MELISA for metal sensitivity testing. Neuro Endocrinol Lett. 24(1–2):57–64.
18.
Fireman E, Shai AB, Alcalay Y, Ophir N, Kivity S, Stejskal V. Identification of metal sensitization in sarcoid-like metal-exposed patients by the MELISA(R) lymphocyte proliferation test - a pilot study. J Occup Med Toxicol. 2016;11:18–016–0101-1 eCollection 2016.CrossRef
19.
Balmes JR, Abraham JL, Dweik RA, Fireman E, Fontenot AP, Maier LA, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. Am J Respir Crit Care Med. 2014;190(10):e34–59.CrossRef
20.
Muller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J. 2006;27(6):1190–5.CrossRef
21.
Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, et al. Job and industry classifications associated with sarcoidosis in a case-control etiologic study of Sarcoidosis (ACCESS). J Occup Environ Med. 2005;47(3):226–34.CrossRef
22.
Vihlborg P, Bryngelsson IL, Andersson L, Graff P. Risk of sarcoidosis and seropositive rheumatoid arthritis from occupational silica exposure in Swedish iron foundries: a retrospective cohort study. BMJ Open. 2017;7(7):e016839 -2017–016839.CrossRef
23.
De Vuyst P, Dumortier P, Schandene L, Estenne M, Verhest A, Yernault JC. Sarcoidlike lung granulomatosis induced by aluminum dusts. Am Rev Respir Dis. 1987;135(2):493–7.PubMed
24.
Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993;262(5131):242–4.CrossRef
25.
McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol. 2003;157(5):388–98.CrossRef
26.
Kromhout H, Vermeulen R. Application of job-exposure matrices in studies of the general population: some clues to their performance. Eur Respir Rev. 2001;11:80–90.
27.
Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet (London, England). 2004;363(9407):415–6.CrossRef
28.
Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis. 1992;145(5):1212–4.CrossRef
29.
Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis. 1988;5(1):51–5.PubMed
30.
Sweiss NJ, Salloum R, Gandhi S, Alegre ML, Sawaqed R, Badaracco M, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One. 2010;5(2):e9088.CrossRef
31.
Clayton GM, Wang Y, Crawford F, Novikov A, Wimberly BT, Kieft JS, et al. Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. Cell. 2014;158(1):132–42.CrossRef
32.
Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am J Ind Med. 2004;46(5):453–62.CrossRef
Metadata
Title
Immunoreactivity to metal and silica associates with sarcoidosis in Dutch patients
Authors
E. Beijer
B. Meek
X. Bossuyt
S. Peters
R. C. H. Vermeulen
H. Kromhout
M. Veltkamp
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01409-w

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue

Research

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)

Research

HGF alleviates septic endothelial injury by inhibiting pyroptosis via the mTOR signalling pathway

Research

Dyspnea, effort and muscle pain during exercise in lung transplant recipients: an analysis of their association with cardiopulmonary function parameters using machine learning

Research

Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

Research

Effects of prostaglandin E1 nebulization of ventilated lung under 60%O2 one lung ventilation on patients’ oxygenation and oxidative stress: a randomised controlled trial

Research

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits